Pasritamig (JNJ-78278343), docetaxel, prednisolone clinical trials

A Phase III randomized, open-label study of pasritamig (JNJ-78278343), a T-cell-redirecting agent targeting human kallikrein 2, with docetaxel versus docetaxel for metastatic castration-resistant prostate cancer

This study is testing a new drug, pasritamig, with an existing treatment for advanced prostate cancer called docetaxel. It aims to see if combining them works better than docetaxel alone for men whose cancer has spread and is resistant to hormone treatment.